Cladribine therapy for systemic mastocytosis

HC Kluin-Nelemans*, JM Oldhoff, JJ van Doormaal, JW van 't Wout, G Verhoef, WBJ Gerrits, OA van Dobbenburgh, SG Pasmans, R Fijnheer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

188 Citations (Scopus)

Abstract

Patients with systemic mastocytosis (SM) can suffer from disabling symptoms related to mast cell mediator release or mast cell infiltration, requiring mast cell eradication. In the present absence of any curative therapy, a recent case report describing the efficacy of cladribine showed promising results. In a pilot study, the efficacy of cladribine (0.10-0.13 mg/kg in a 2-hour infusion, days 1-5; repeated at 4-8 weeks until 6 cycles) was studied. Ten patients with SM with severe symptoms were treated. Four patients were classified as having indolent or smoldering mastocytosis, 3 as having aggressive systemic mastocytosis, and 3 as having SM with an accompanying hematologic malignancy. Nine patients received 6 courses, 1 patient stopped because of toxicodermia. All responded concerning signs, symptoms, and mast cell parameters (serum tryptase and urinary histamine metabolite excretion), although none achieved a complete remission. Prolonged follow-up is required, as response is ongoing in most cases. One patient relapsed within 11 months and showed a second response. Side effects were mainly related to bone marrow suppression. Single-agent cladribine is an effective and relatively safe treatment for severe systemic mastocytosis. The optimal dose and schedule need to be explored. (C) 2003 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)4270-4276
Number of pages7
JournalBlood
Volume102
Issue number13
DOIs
Publication statusPublished - 15-Dec-2003

Keywords

  • MAST-CELL DISEASE
  • INTERFERON-ALPHA
  • C-KIT
  • URTICARIA
  • HISTAMINE
  • DISORDERS
  • MUTATION
  • PATIENT

Cite this